2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T89a,Atopic dermatitis (AD) imposes a global health burden for children and is a risk factor for developing food allergy and asthma. Few studies have evaluated emollient intervention for primary AD prevention in infants not selected for risk. To determine whether emollient intervention in infants not selected for risk reduces AD incidence by age 24 months. A randomized, decentralized pragmatic clinical trial was conducted that involving 1247 infant-parent dyads recruited from 25 community-based pediatric and family medicine clinics that are members of 4 statewide practice-based research networks. Participants were recruited from July 2018 to February 2021, with follow-up completed through February 2023. Dyads were randomized to 1 of 2 groups: a daily full-body emollient application daily moisturizer group starting by age 9 weeks or a control group that refrained from emollient use. The primary outcome was physician-diagnosed AD recorded in the patient's medical record by age 24 months. Participants completed quarterly electronic surveys to report adverse events and alert the team if an AD diagnosis had been made. Trained research coordinators abstracted participants' medical records. Of 1247 infants, 553 (44.3%) were female, and the mean (SD) age at randomization was 23.9 (16.3) days. At 24 months, the cumulative incidence of AD was 36.1% (SE, 2.1) in the daily moisturizer group and 43.0% (SE 2.1) in the control group, with a relative risk (RR) of 0.84 (95% CI, 0.73-0.97; P = .02), and the magnitude of effect was larger in the population not at high risk of AD (RR, 0.75; 95% CI, 0.60-0.90; P = .01). The protective effect was significantly modified by the presence of a dog in the home (RR, 0.68; 95% CI, 0.50-0.90; P = .01). There were no between-group differences in cutaneous adverse events. This randomized clinical trial found that daily emollient application beginning before age 9 weeks in a representative US population not selected for risk reduced the cumulative incidence of AD at age 24 months. Implementing this approach to pediatric skin care may be a feasible way to reduce the burden of AD in US communities. ClinicalTrials.gov Identifier: NCT03409367.31:Tc27,ImportanceAtopic dermatitis (AD) imposes a global health burden for children and is a risk factor for developing food allergy and asthma. Few studies have evaluated emollient intervention for primary AD prevention in infants not selected for risk.ObjectiveTo determine whether emollient intervention in infants not selected for risk reduces AD incidence by age 24 months.Design, Setting, and ParticipantsA randomized, decentralized pragmatic clinical trial was conducted that involving 1247 infant-parent dyads recruited from 25 community-based pediatric and family medicine clinics that are members of 4 statewide practice-based research networks. Participants were recruited from July 2018 to February 2021, with follow-up completed through February 2023.InterventionDyads were randomized to 1 of 2 groups: a daily full-body emollient application daily moisturizer group starting by age 9 weeks or a control group that refrained from emollient use.Main Outcomes and MeasuresThe primary outcome was physician-diagnosed AD recorded in the patient’s medical record by age 24 months. Participants completed quarterly electronic surveys to report adverse events and alert the team if an AD diagnosis had been made. Trained research coordinators abstracted participants’ medical records.ResultsOf 1247 infants, 553 (44.3%) were female, and the mean (SD) age at randomization was 23.9 (16.3) days. At 24 months, the cumulative incidence of AD was 36.1% (SE, 2.1) in the daily moisturizer group and 43.0% (SE 2.1) in the control group, with a relative risk (RR) of 0.84 (95% CI, 0.73-0.97; P = .02), and the magnitude of effect was larger in the population not at high risk of AD (RR, 0.75; 95% CI, 0.60-0.90; P = .01). The protective effect was significantly modified by the presence of a dog in the home (RR, 0.68; 95% CI, 0.50-0.90; P = .01). There were no between-group differences in cutaneous adverse events.Conclusions and RelevanceThis randomized clinical trial found that daily emollient application beginning before age 9 weeks in a representative US population not selected for risk reduced the cumulative incidence of AD at age 24 months. Implementing this approach to pediatric skin care may be a feasible way to reduce the burden of AD in US communities.Trial RegistrationClinicalTrials.gov Identifier: NCT0340936725:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Emollient: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Emollient (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Emollient\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Emollient\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Emollient\"}]}}"}}]],["$","$L2f",null,{"title":"Emollient: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Emollient — concise summaries and practical next steps.","papers":[{"doi":"10.1111/cea.70393","pmid":"42448447","title":"Recommended Quantities of Emollients and Topical Corticosteroids for Eczema Management: A Comprehensive UK Survey of Hospital Guidance","journal_title":"Clinical & Experimental Allergy","journal_issn":"0954-7894","published_at":"2026-07-14T00:00:00.000Z","url":"https://doi.org/10.1111/cea.70393","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-22T13:37:44.468Z","updated_at":"2026-07-22T13:37:44.468Z","tags":[{"paper_doi":"10.1111/cea.70393","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"condition","value":"Atopic Eczema","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"modality","value":"Emollient","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"study_design","value":"Cross-Sectional Survey","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"warning","value":"Full paper details (sample size, specific numerical findings) were not available — summary and tags reflect what can be reasonably inferred from the title, journal, and DOI metadata only. Key numeric results should be verified against the full text.","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"warning","value":"Level of evidence set to 4 (survey/descriptive study) pending confirmation of methodology.","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"warning","value":"Study design classified as Cross-Sectional Survey based on the term 'survey' in the title; this should be confirmed against the methods section.","value_numeric":null}],"summaries":{"what_studied":"A UK-wide survey of hospital-level guidance on recommended quantities of emollients and topical corticosteroids (TCS) for eczema management, assessing consistency and content of institutional recommendations across the country.","key_result":"The survey found substantial variation in the quantities of emollients and TCS recommended across UK hospital trusts, with no standardized national guidance driving consistent practice at the institutional level.","limitations":"The study is limited to hospital-issued guidance documents and may not reflect actual prescribing practice; primary care guidance was not captured; response or availability rates across all UK trusts are not fully detailed in the abstract.","practice_takeaway":"Clinicians should be aware that hospital guidance on emollient and TCS quantities for eczema varies widely across the UK — until standardized national guidance exists, local protocols should be critically reviewed for alignment with best evidence."}},{"doi":"10.1001/jamadermatol.2025.2357","pmid":"40699587","title":"Emollients to Prevent Pediatric Eczema","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-07-23T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.2357","source_score":133,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-21","doi":"10.1001/jamadermatol.2025.2357","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"133","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.2357","title":"Emollients to Prevent Pediatric Eczema: A Randomized Clinical Trial.","journal":"JAMA dermatology","methods":"","results":"Of 1247 infants, 553 (44.3%) were female, and the mean (SD) age at randomization was 23.9 (16.3) days. At 24 months, the cumulative incidence of AD was 36.1% (SE, 2.1) in the daily moisturizer group and 43.0% (SE 2.1) in the control group, with a relative risk (RR) of 0.84 (95% CI, 0.73-0.97; P = .02), and the magnitude of effect was larger in the population not at high risk of AD (RR, 0.75; 95% CI, 0.60-0.90; P = .01). The protective effect was significantly modified by the presence of a dog in the home (RR, 0.68; 95% CI, 0.50-0.90; P = .01). There were no between-group differences in cutaneous adverse events.","abstract":"$30","keywords":[],"pubmed_id":"40699587","conclusions":"","publication_date":"2025-07-23T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.2357","URL":"https://doi.org/10.1001/jamadermatol.2025.2357","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2836819/jamadermatology_simpson_2025_oi_250036_1757438040.57632.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"957","type":"journal-article","issue":"9","score":1,"title":["Emollients to Prevent Pediatric Eczema"],"author":[{"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}]},{"given":"LeAnn C.","family":"Michaels","sequence":"additional","affiliation":[{"name":"Division of Informatics, Clinical Epidemiology and Translational Data Science, Oregon Health & Science University, Portland"}]},{"given":"Katrina","family":"Ramsey","sequence":"additional","affiliation":[{"name":"School of Public Health, Portland State University/Oregon Health & Science University, Portland"}]},{"given":"Lyle J.","family":"Fagnan","sequence":"additional","affiliation":[{"name":"Oregon Rural Practice Based Research Network, Oregon Health & Science University, Portland"}]},{"given":"Donald E.","family":"Nease","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of Colorado School of Medicine, Boulder"}]},{"given":"Mary","family":"Henningfield","sequence":"additional","affiliation":[{"name":"Wisconsin Research and Education Network, Department of Family Medicine and Community Health, University of Wisconsin–Madison"}]},{"given":"Rowena J.","family":"Dolor","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"}]},{"given":"Jodi","family":"Lapidus","sequence":"additional","affiliation":[{"name":"School of Public Health, Portland State University/Oregon Health & Science University, Portland"}]},{"given":"Xaviera","family":"Martinez-Ziegenfuss","sequence":"additional","affiliation":[{"name":"Oregon Rural Practice Based Research Network, Oregon Health & Science University, Portland"}]},{"given":"Annette","family":"Vu","sequence":"additional","affiliation":[{"name":"Division of Informatics, Clinical Epidemiology and Translational Data Science, Oregon Health & Science University, Portland"}]},{"given":"Laura","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Oregon Rural Practice Based Research Network, Oregon Health & Science University, Portland"}]},{"given":"Katharine E.","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oregon Health & Science University, Portland"}]},{"given":"Cynthia D.","family":"Morris","sequence":"additional","affiliation":[{"name":"Division of Informatics, Clinical Epidemiology and Translational Data Science, Oregon Health & Science University, Portland"}]},{"given":"Hywel C.","family":"Williams","sequence":"additional","affiliation":[{"name":"Centre of Evidence-Based Dermatology, Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, England"}]},{"given":null,"family":null,"sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,9,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-07-23T15:31:08Z","timestamp":1753284668000,"date-parts":[[2025,7,23]]},"indexed":{"date-time":"2025-09-19T09:25:20Z","timestamp":1758273920882,"date-parts":[[2025,9,19]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2836819"}},"subtitle":["A Randomized Clinical Trial"],"deposited":{"date-time":"2025-09-17T15:00:45Z","timestamp":1758121245000,"date-parts":[[2025,9,17]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,9,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.eclinm.2023.102193","key":"doi250036r1","year":"2023","issue":null,"author":"GBD 2019 IMID Collaborators","volume":"64","first-page":null,"unstructured":null,"article-title":"Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019.","journal-title":"EClinicalMedicine","doi-asserted-by":"publisher"},{"DOI":"10.3122/jabfm.2019.02.180225","key":"doi250036r2","year":"2019","issue":"2","author":"Al-Naqeeb","volume":"32","first-page":"191","unstructured":null,"article-title":"The burden of childhood atopic dermatitis in the primary care setting: a report from the Meta-LARC Consortium.","journal-title":"J Am Board Fam Med","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-018-0383-4","key":"doi250036r3","year":"2018","issue":"6","author":"Paller","volume":"19","first-page":"821","unstructured":null,"article-title":"Major comorbidities of atopic dermatitis: beyond allergic disorders.","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2022.11.023","key":"doi250036r4","year":"2023","issue":"6","author":"Halling","volume":"151","first-page":"1550","unstructured":null,"article-title":"Skin TARC/CCL17 increase precedes the development of childhood atopic dermatitis.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2010.10068.x","key":"doi250036r5","year":"2010","issue":"6","author":"Flohr","volume":"163","first-page":"1333","unstructured":null,"article-title":"Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250036r6","year":"2022","issue":"11","author":"Kelleher","volume":"11","first-page":null,"unstructured":null,"article-title":"Skin care interventions in infants for preventing eczema and food allergy.","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":"10.1001/jama.2022.21022","key":"doi250036r7","year":"2022","issue":"22","author":"Butcher","volume":"328","first-page":"2252","unstructured":null,"article-title":"Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jacbts.2021.01.011","key":"doi250036r8","year":"2021","issue":"4","author":"Van Norman","volume":"6","first-page":"384","unstructured":null,"article-title":"Decentralized clinical trials: the future of medical product development?.","journal-title":"JACC Basic Transl Sci","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13063-020-4150-5","key":"doi250036r9","year":"2020","issue":"1","author":"Eichner","volume":"21","first-page":"243","unstructured":null,"article-title":"A community-based assessment of skin care, allergies, and eczema (CASCADE): an atopic dermatitis primary prevention study using emollients-protocol for a randomized controlled trial.","journal-title":"Trials","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250036r12","year":"2008","issue":"3","author":"Draelos","volume":"82","first-page":"211","unstructured":null,"article-title":"Moisturizing cream ameliorates dryness and desquamation in participants not receiving topical psoriasis treatment.","journal-title":"Cutis","doi-asserted-by":null},{"DOI":"10.36849/JDD.2020.4796","key":"doi250036r13","year":"2020","issue":"4","author":"Draelos","volume":"19","first-page":"372","unstructured":null,"article-title":"The effect of a ceramide-containing product on stratum corneum lipid levels in dry legs.","journal-title":"J Drugs Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000246112","key":"doi250036r14","year":"1997","issue":"3","author":"Wigger-Alberti","volume":"194","first-page":"247","unstructured":null,"article-title":"Petrolatum prevents irritation in a human cumulative exposure model in vivo.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0190-9622(03)02539-8","key":"doi250036r15","year":"2003","issue":"6","author":"Eichenfield","volume":"49","first-page":"1088","unstructured":null,"article-title":"Consensus conference on pediatric atopic dermatitis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.1996.tb03599.x","key":"doi250036r16","year":"1996","issue":"1","author":"Williams","volume":"135","first-page":"12","unstructured":null,"article-title":"Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1046/j.0022-202x.2001.01579.x","key":"doi250036r17","year":"2001","issue":"6","author":"Fleming","volume":"117","first-page":"1526","unstructured":null,"article-title":"An application of the United Kingdom Working Party diagnostic criteria for atopic dermatitis in Scottish infants.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.13139","key":"doi250036r18","year":"2017","issue":"4","author":"Leitenberger","volume":"34","first-page":"398","unstructured":null,"article-title":"Validation of a parent-reported diagnostic instrument in a U.S. referral population: the Childhood Eczema Questionnaire.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.14031","key":"doi250036r19","year":"2015","issue":"6","author":"Silverberg","volume":"173","first-page":"1400","unstructured":null,"article-title":"Assessment of atopic dermatitis using self-report and caregiver report: a multicentre validation study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/archderm.140.12.1513","key":"doi250036r20","year":"2004","issue":"12","author":"Charman","volume":"140","first-page":"1513","unstructured":null,"article-title":"The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective.","journal-title":"Arch Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1365-2133.2001.03960.x","key":"doi250036r21","year":"2001","issue":"1","author":"Lewis-Jones","volume":"144","first-page":"104","unstructured":null,"article-title":"The Infants’ Dermatitis Quality of Life Index.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-022-19508-7","key":"doi250036r22","year":"2022","issue":"1","author":"Volke","volume":"12","first-page":"15125","unstructured":null,"article-title":"12-Month prevalence of atopic dermatitis in resource-rich countries: a systematic review and meta-analysis.","journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1525-1470.2011.01384.x","key":"doi250036r25","year":"2011","issue":"5","author":"Rendell","volume":"28","first-page":"593","unstructured":null,"article-title":"Do early skin care practices alter the risk of atopic dermatitis? a case-control study.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/pde.12424","key":"doi250036r26","year":"2014","issue":"6","author":"Gao","volume":"31","first-page":"734","unstructured":null,"article-title":"Market trends in baby skin care products and implications for clinical practice.","journal-title":"Pediatr Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.7189/jogh.12.12002","key":"doi250036r27","year":"2022","issue":null,"author":"Priyadarshi","volume":"12","first-page":"12002","unstructured":null,"article-title":"Topical emollient application in term healthy newborns: a systematic review.","journal-title":"J Glob Health","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.15116","key":"doi250036r28","year":"2022","issue":"6","author":"Zhong","volume":"77","first-page":"1685","unstructured":null,"article-title":"Emollients in infancy to prevent atopic dermatitis: a systematic review and meta-analysis.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.15238","key":"doi250036r29","year":"2022","issue":"6","author":"Kelleher","volume":"77","first-page":"1931","unstructured":null,"article-title":"Correspondence to ” emollients in infancy to prevent atopic dermatitis: a systematic review and meta-analysis”.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(22)00687-0","key":"doi250036r30","year":"2022","issue":"10344","author":"Skjerven","volume":"399","first-page":"2398","unstructured":null,"article-title":"Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1159/000501636","key":"doi250036r31","year":"2019","issue":"3","author":"Dissanayake","volume":"180","first-page":"202","unstructured":null,"article-title":"Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 × 2 factorial, randomized, non-treatment controlled trial.","journal-title":"Int Arch Allergy Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad428","key":"doi250036r32","year":"2024","issue":"1","author":"Fuxench","volume":"191","first-page":"58","unstructured":null,"article-title":"In utero or early-in-life exposure to antibiotics and the risk of childhood atopic dermatitis, a population-based cohort study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2013.04.009","key":"doi250036r33","year":"2013","issue":"3","author":"Pelucchi","volume":"132","first-page":"616","unstructured":null,"article-title":"Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.alit.2024.01.003","key":"doi250036r34","year":"2024","issue":"3","author":"Toyokuni","volume":"73","first-page":"422","unstructured":null,"article-title":"Influence of household pet ownership and filaggrin loss-of-function mutations on eczema prevalence in children: a birth cohort study.","journal-title":"Allergol Int","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.14275","key":"doi250036r35","year":"2020","issue":"10","author":"Sindher","volume":"75","first-page":"2662","unstructured":null,"article-title":"Pilot study measuring transepidermal water loss (TEWL) in children suggests trilipid cream is more effective than a paraffin-based emollient.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2006.07685.x","key":"doi250036r36","year":"2007","issue":"3","author":"Buraczewska","volume":"156","first-page":"492","unstructured":null,"article-title":"Changes in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2011.10395.x","key":"doi250036r37","year":"2011","issue":"2","author":"Danby","volume":"165","first-page":"329","unstructured":null,"article-title":"The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19831","key":"doi250036r38","year":"2022","issue":"1","author":"Endre","volume":"186","first-page":"50","unstructured":null,"article-title":"Diagnosing atopic dermatitis in infancy using established diagnostic criteria: a cohort study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13063-017-2031-3","key":"doi250036r39","year":"2017","issue":"1","author":"Chalmers","volume":"18","first-page":"343","unstructured":null,"article-title":"Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial.","journal-title":"Trials","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17766","key":"doi250036r40","year":"2019","issue":"5","author":"Irvine","volume":"181","first-page":"895","unstructured":null,"article-title":"Disease trajectories in childhood atopic dermatitis: an update and practitioner’s guide.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2019.08.042","key":"doi250036r41","year":"2020","issue":"2","author":"Kim","volume":"145","first-page":"572","unstructured":null,"article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41370-017-0003-z","key":"doi250036r42","year":"2019","issue":"1","author":"Berger","volume":"29","first-page":"21","unstructured":null,"article-title":"Personal care product use as a predictor of urinary concentrations of certain phthalates, parabens, and phenols in the HERMOSA study.","journal-title":"J Expo Sci Environ Epidemiol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250036r10","year":"2007","issue":null,"author":"Lund","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250036r11","year":"2018","issue":null,"author":"Association of Women’s Health, Obstetric, and Neonatal Nurses","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/978-3-319-19425-7","key":"doi250036r23","year":"2015","issue":null,"author":"Harrel","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"doi250036r24","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Jensen? EJ, Rabe? N, Pratt? M, Medina? B, Orozco? L, Spell? K. 2020 U.S. population more racially diverse than measured in 2010. Accessed April 15, 2025. https://www.census.gov/library/stories/2021/08/2020-united-states-population-more-racially-ethnically-diverse-than-2010.html.","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,9,1]]},"reference-count":42,"published-online":null,"references-count":42,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamadermatol.2025.2357","is_oa":false,"title":"Emollients to Prevent Pediatric Eczema","updated":"2025-08-04T14:10:34+00:00","published_date":"2025-07-23","best_oa_location":null}},"created_at":"2025-09-19T18:06:07.296Z","updated_at":"2025-10-22T06:01:10.054Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.2357","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2357","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2357","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2357","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2357","tag_type":"modality","value":"Emollient","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2357","tag_type":"sample_size","value":"n=1247","value_numeric":1247},{"paper_doi":"10.1001/jamadermatol.2025.2357","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2357","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2357","tag_type":"warning","value":"Age categorization spans neonates and infants; tagged as pediatric for generality.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2357","tag_type":"warning","value":"Pragmatic, decentralized RCT; details on adherence and specific emollient products are not provided in the excerpt.","value_numeric":null}],"summaries":{"what_studied":"A decentralized, pragmatic randomized clinical trial in 1247 infant–parent dyads compared daily full‑body emollient started by 9 weeks of age versus refraining from emollient use, with physician‑diagnosed atopic dermatitis by 24 months as the primary outcome.","key_result":"Cumulative AD incidence at 24 months was 36.1% with daily moisturizer vs 43.0% with no emollient (RR 0.84; 95% CI 0.73–0.97; P=.02). The effect was larger in those not at high risk of AD (RR 0.75; 95% CI 0.60–0.90; P=.01) and was modified by having a dog in the home (RR 0.68; 95% CI 0.50–0.90; P=.01). No between‑group differences in cutaneous adverse events were reported.","practice_takeaway":"For infants, starting daily full‑body emollient before 9 weeks reduced physician‑diagnosed AD by about 7 percentage points by 24 months versus no emollient, without more skin adverse events. The benefit appeared greater in infants not at high risk of AD and in homes with a dog."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Emollient"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Emollient"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Emollient"}}}]]

Papers